Plain-English translation of NCT04981509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and —to treat advanced kidney cancer. The study focuses on two types of kidney cancer: a rare hereditary form called HLRCC-associated kidney cancer and a more common form called papillary kidney cancer. Researchers want to see if giving these three drugs together can shrink tumors and help people live longer.
Advanced kidney cancer is difficult to treat, and current treatments don't work well enough for everyone. This medication combination uses three different approaches at once—one that cuts off blood supply to tumors, one that targets cancer cells directly, and one that helps the immune system fight cancer—to see if attacking the disease from multiple angles works better.
You likely qualify if…
You likely don't qualify if…
You will receive two of the medications ( and ) as intravenous infusions on day 1 of each treatment cycle, and take the third medication () as a daily pill for 21 days. Each cycle repeats every 3 weeks. You will have regular imaging scans (CT or MRI), blood tests throughout your participation, and possibly biopsies to monitor how the treatment is working and check for side effects. The treatment continues as long as the cancer is not growing and you are tolerating the medication well.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States